JAC Advance Access originally published online on November 24, 2004
Journal of Antimicrobial Chemotherapy 2005 55(1):31-37; doi:10.1093/jac/dkh507
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma
Department of Dermatology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, No. 8 Xishiku St, West District, Beijing, 100034, People's Republic of China
* Corresponding author. Tel: +86-10-66155335; Fax: +86-10-66155335; Email: lrywdh{at}public.bta.net.cn
Objectives: To monitor changes in itraconazole susceptibility of isolates from a patient undergoing treatment for pulmonary Aspergillus infection and relate these changes to genotypic/phenotypic alterations.
Methods: Six Aspergillus fumigatus isolates were serially recovered from the patient. Itraconazole MICs were determined by Etest and NCCLS methodology. Growth characteristics and phenotype were monitored. Molecular analysis included random amplified polymorphic DNA (RAPD) assay and sequencing of the cyp51A gene.
Results: The MIC of itraconazole against the first isolate before treatment was 0.25 mg/L; the MIC against the second isolate, recovered after 6 months of itraconazole therapy, was >16 mg/L; and that against the third isolate, obtained 2 months after discontinuation of the therapy, was 0.5 mg/L. The MIC against the last three isolates, acquired after restoration of itraconazole therapy for 4–7 months, was >16 mg/L. The six isolates shared identical band patterns of RAPD assay using four primers and the same sequence in intertranscribed spacers (ITS). Therefore, the six isolates were likely to be the same strain of A. fumigatus, and mutations involving itraconazole resistance possibly occurred in these isolates after prolonged itraconazole therapy. Sequencing of the cyp51A gene in the coding region revealed a mutation of M220I in cytochrome P450 sterol 14-
-demethylase in the second resistant isolate and a mutation of G54R in the last three resistant isolates. Expression changes of some pump genes, such as MDR3, may also, in part, be related to the resistance to itraconazole.
Conclusions: We conclude that resistance of A. fumigatus to itraconazole occurred in a patient treated with the drug, and the resistance may result from mutations in the cyp51A gene—the gene encoding the target enzyme for itraconazole.
Keywords: azole antifungals , resistance , genetics , MICs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Mavridou, R. J. M. Bruggemann, W. J. G. Melchers, J. W. Mouton, and P. E. Verweij Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene Antimicrob. Agents Chemother., February 1, 2010; 54(2): 860 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, et al. Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods J. Clin. Microbiol., October 1, 2009; 47(10): 3142 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk Efflux-Mediated Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Arendrup, S. Perkhofer, S. J. Howard, G. Garcia-Effron, A. Vishukumar, D. Perlin, and C. Lass-Florl Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus: the Challenge of Azoles versus Echinocandins Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3504 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species J. Clin. Microbiol., August 1, 2008; 46(8): 2568 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Rodriguez-Tudela, L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2468 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garcia-Effron, A. Dilger, L. Alcazar-Fuoli, S. Park, E. Mellado, and D. S. Perlin Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus J. Clin. Microbiol., April 1, 2008; 46(4): 1200 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Rodriguez-Tudela, L. Alcazar-Fuoli, A. Alastruey-Izquierdo, A. Monzon, E. Mellado, and M. Cuenca-Estrella Time of Incubation for Antifungal Susceptibility Testing of Aspergillus fumigatus: Can MIC Values Be Obtained at 24 Hours? Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4502 - 4504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mellado, G. Garcia-Effron, L. Alcazar-Fuoli, W. J. G. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations Antimicrob. Agents Chemother., June 1, 2007; 51(6): 1897 - 1904. [Abstract] [Full Text] [PDF]
|
|